PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Cancer Research

Principle and Setup: Targeting Focal Adhesion Kinase Signaling

Focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) are pivotal non-receptor tyrosine kinases orchestrating cancer cell adhesion, migration, proliferation, and survival. Aberrant FAK signaling contributes to tumor growth, metastasis, and immune evasion, making the pathway a prime target in oncology. PF-562271 HCl, supplied by APExBIO, is a highly selective, ATP-competitive FAK/Pyk2 inhibitor. It offers an IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, displaying over 100-fold selectivity against most other kinases except select CDKs (product information).

This reversible inhibitor allows researchers to finely modulate FAK and Pyk2 activity in both in vitro and in vivo models, providing a robust platform to interrogate tumor biology, microenvironment modulation, and therapeutic resistance mechanisms. Its utility is further amplified in combination studies, including those leveraging immunotherapy and radiotherapy (reference study).

Step-by-Step Workflow: Enhancing Experimental Rigor

PF-562271 HCl's operational reliability and solubility profile enable seamless integration into cancer research workflows. Below is a stepwise guide for incorporating this FAK/Pyk2 inhibitor into experimental models:

• Compound Preparation: Dissolve PF-562271 HCl in DMSO at concentrations up to 26.35 mg/mL with gentle warming. The compound is insoluble in water and ethanol, making DMSO the preferred vehicle for both cell-based and animal studies (PF-562271 HCl product page).
• In Vitro Assays: Treat cancer cell lines with PF-562271 HCl at concentrations ranging from 10 nM to 1 µM. Preincubate cells for 30–60 minutes prior to stimulus or treatment to ensure effective FAK phosphorylation inhibition, as corroborated by EC₅₀ values around 93 ng/mL for pFAK suppression.
• In Vivo Models: For tumor xenograft or transgenic mouse models, administer PF-562271 HCl via daily intraperitoneal injections at literature-backed doses (e.g., 25–50 mg/kg). Monitor tumor volume and metastatic burden, with endpoint analyses for phosphorylated FAK/Pyk2 and immune infiltration markers.

Protocol Parameters

• Stock solution preparation: Dissolve PF-562271 HCl at 26.35 mg/mL in DMSO; vortex and gently warm to 37°C to fully solubilize.
• In vitro dosing: Apply at 100 nM–1 µM final concentration for 24–72 hours, with medium renewal every 48 hours to maintain inhibitor activity.
• In vivo administration: Inject 25 mg/kg IP daily for 14–21 days in mouse models; use sterile DMSO/PBS vehicle, not exceeding 5% DMSO (v/v) in injection volume.

Key Innovation from the Reference Study

The reference study presents a breakthrough by demonstrating that radiotherapy combined with dual immune checkpoint blockade (PD-1 and TIGIT inhibition) synergistically enhances antitumor immunity via robust CD8⁺ T cell activation and M1 macrophage polarization. This triple therapy not only regressed primary tumors but also induced abscopal effects—regression of distant, untreated tumors—through durable immune memory.

Practically, this finding suggests that integrating FAK/Pyk2 inhibition with immunotherapy and radiotherapy can potentiate tumor regression and overcome immune resistance. PF-562271 HCl, by modulating tumor microenvironment and reducing immunosuppressive signals, is ideally suited for such combination studies. Researchers can incorporate PF-562271 HCl into triple-therapy protocols to evaluate its impact on immune cell infiltration, memory T cell formation, and abscopal responses in syngeneic or xenograft models, using flow cytometry and immunohistochemistry as readouts.

Advanced Applications and Comparative Advantages

PF-562271 HCl's nanomolar potency and selectivity make it a tool of choice for mechanistic dissection of the FAK signaling axis in cancer research. Its reversible, ATP-competitive inhibition enables controlled, temporal studies of FAK/Pyk2 pathway dynamics and their impact on tumor growth, metastasis, and immune modulation.

Recent publications highlight PF-562271 HCl's role in bridging kinase signaling and immune modulation. For example, one article details how this inhibitor enhances translational studies by optimizing assay conditions for immune cell-tumor interaction analyses. Another complementary resource demonstrates its value in preclinical models that probe the intersection of FAK inhibition and immunotherapy strategies.

Compared to less selective FAK inhibitors, PF-562271 HCl minimizes off-target effects, reducing data confounders and improving reproducibility. Its ability to modulate the tumor microenvironment—including reducing stromal rigidity and immunosuppressive cell populations—enables nuanced modeling of therapeutic resistance and response, as shown in tumor microenvironment modulation studies (see this extension).

Troubleshooting and Optimization Tips

• Solubility issues: If PF-562271 HCl appears partially insoluble, gently warm the DMSO stock to 37°C and vortex thoroughly. Avoid water or ethanol as solvents, which will precipitate the compound.
• Inconsistent FAK inhibition: Ensure that cells or animals are pre-treated for the recommended duration and at the optimal concentration. Validate pathway inhibition by immunoblotting for phosphorylated FAK (Y397) and Pyk2.
• Batch variability: Use the same lot of PF-562271 HCl from a trusted supplier such as APExBIO to ensure analytical consistency across experiments. Store aliquots at -20°C, protected from light and moisture.
• Synergy with immunotherapy: When combining with immune checkpoint inhibitors or radiotherapy, stagger administration times based on pharmacokinetics—e.g., dose PF-562271 HCl 1–2 hours before irradiation or antibody injection to synchronize pathway inhibition and immune priming.
• Data interpretation: Employ appropriate controls, including DMSO vehicle and single-agent treatments, to attribute effects specifically to FAK/Pyk2 inhibition.

Future Outlook: Integrating FAK Inhibition into Next-Gen Cancer Therapies

The evidence from the reference study points to a rapidly maturing paradigm where FAK/Pyk2 inhibitors like PF-562271 HCl are not merely cytostatic agents, but potent modulators of tumor immune contexture. By facilitating CD8⁺ T cell activation, enhancing M1 macrophage function, and promoting durable immune memory, PF-562271 HCl is positioned at the intersection of targeted therapy and immuno-oncology.

These properties open translational avenues for researchers to design combination regimens that address immune resistance—a bottleneck in PD-1/PD-L1 monotherapy. As the mechanistic underpinnings of abscopal effects and immune memory become clearer, selective FAK/Pyk2 inhibition will likely become a staple in advanced preclinical and early-phase clinical trials, accelerating precision medicine strategies in oncology.

For laboratories seeking reliability and rigorous control in their cancer research workflows, PF-562271 HCl from APExBIO remains a premier choice, enabling deep mechanistic insights and translational relevance in the evolving landscape of cancer therapeutics.